home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

66.90 +8.02 (+13.62%)

Streaming Delayed Price Updated: 10:15 AM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Expert Ratings for AnaptysBio ↗

November 09, 2022

Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

AnaptysBio to Participate in Upcoming November Investor Conferences

November 09, 2022

From AnaptysBio, Inc.

Via GlobeNewswire

AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

November 08, 2022

From AnaptysBio, Inc.

Via GlobeNewswire

AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial ↗

October 05, 2022

Via Benzinga

HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround ↗

September 19, 2022

Via Benzinga

AnaptysBio Sells Royalty Interest In Cancer Drug For $45M ↗

September 12, 2022

Via Benzinga

Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback ↗

September 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

October 05, 2022

From AnaptysBio, Inc.

Via GlobeNewswire

Short Volatility Alert: AnaptysBio, Inc. ↗

May 26, 2022

On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment...

Via Benzinga

AnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers ↗

April 28, 2022

Via Benzinga

This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle ↗

September 13, 2022

Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022 ↗

September 13, 2022

Upgrades See all analyst ratings upgrades.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗

September 01, 2022

Upgrades

Via Benzinga

AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication ↗

September 01, 2022

AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 01, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 31, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

June 07, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

June 02, 2022

During the Thursday's session, 100 stocks hit new 52-week lows.

Via Benzinga

AnaptysBio's Return On Capital Employed Insights ↗

May 24, 2022

Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter.

Via Benzinga

Recap: AnaptysBio Q4 Earnings ↗

March 07, 2022

AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2022 ↗

March 22, 2022

Upgrades For Procter & Gamble Co (NYSE:PG), Truist Securities upgraded the previous rating of Hold to Buy. For the second quarter, Procter & Gamble had an EPS of $1.66,...

Via Benzinga

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗

March 22, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne ↗

March 15, 2022

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne

Via Benzinga

The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗

March 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 14, 2022

Gainers Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.

Via Benzinga

AnaptysBio's Return On Capital Employed Insights ↗

March 10, 2022

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of...

Via Benzinga

Hoth Therapeutics Reports Being Set To Begin Phase 2 Study On First-Of-Its-Kind Skin Toxicity Ointment For Cancer Patients ↗

February 01, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com